Evaluation of Tangible Boost Replenishing System

October 23, 2020 updated by: Tangible Science
This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating improves lens wettability, a common cause of patient discomfort. Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Houston, Texas, United States, 77204
        • University of Houston

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Habitual contact lens wear with a group 3 FDA approved rigid lens material, with 20-50% of subjects wearing corneal lenses
  • Willing and able to sign the informed consent form
  • 18 years or older

Exclusion Criteria:

  • Eye injury or surgery within the 3 months immediately prior to enrollment for this trial
  • Pre-existing ocular irritation that would preclude contact lens fitting
  • Current enrollment in an ophthalmic clinical trial
  • Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of the accessory solutions, as determined by the investigator
  • Any use of medications for which contact lens wear could be contraindicated, as determined by the investigator
  • Pregnant women and nursing mothers
  • Visual acuity less than 20/20 when best corrected with contact lenses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Tangible Boost
Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
PLACEBO_COMPARATOR: Control
Participants will treat their lenses with a placebo "Tangible Boost" kit containing saline after 30 days and again after 60 days.
Participants will treat their lenses with a placebo "Tangible Boost" kit, which contains saline in place of the Tangible Boost solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Patients With Adverse Event Reports or Discontinuations
Time Frame: Duration of study, 90 +/- 7 days after lens dispense visit.
A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.
Duration of study, 90 +/- 7 days after lens dispense visit.
Corneal Staining
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.
1 day after treatment (day 31), final assessment (day 90)
Visual Acuity
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.
1 day after treatment (day 31), final assessment (day 90)
Non-invasive Tear Film Break-up Time
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
Tear break-up time was measured with the OCULUS Keratograph.
1 day after treatment (day 31), final assessment (day 90)
Number of Participants With Acceptable Lens Fit
Time Frame: final assessment (day 90)
Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).
final assessment (day 90)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CLDEQ Score
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.
1 day after treatment (day 31), final assessment (day 90)
Visual Analog Scale (VAS)
Time Frame: 1 day after treatment (day 31), final assessment (day 90)
The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.
1 day after treatment (day 31), final assessment (day 90)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Maria K Walker, OD MS, University of Houston

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 24, 2017

Primary Completion (ACTUAL)

February 13, 2019

Study Completion (ACTUAL)

February 13, 2019

Study Registration Dates

First Submitted

February 28, 2017

First Submitted That Met QC Criteria

March 2, 2017

First Posted (ACTUAL)

March 8, 2017

Study Record Updates

Last Update Posted (ACTUAL)

November 17, 2020

Last Update Submitted That Met QC Criteria

October 23, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 113133

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Contact Lens Solution

Clinical Trials on Tangible Boost

Subscribe